Moderna's Flu Vaccine Struggles: Is Novavax Stock Now a Better Buy?
Moderna (NASDAQ: MRNA) knows that it needs new products. The good news is that Moderna has three vaccine candidates in late-stage testing. Moderna reported more disappointing results for its experimental flu vaccine last week.